Regulations and Regulatory Advocacy
The AHA today submitted comments on the Food and Drug Administration’s revised draft guidance on hospital and health system compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act.
The Centers for Medicare & Medicaid Services (CMS) has released six documents updating previous guidance implementing the No Surprises Act requirements regarding Standard Notice and Consent Forms and Model Public Disclosure Notices.
At A Glance
Please note, on Dec. 11, President Biden signed legislation that delays by one year (until Jan. 1, 2023) the clinical laboratory reporting requirements discussed in this advisory. It also delays for one year payment cuts under the CLFS that would have otherwise been imposed starting…
We appreciate CMS’ issuance of a streamlined rule, which allows HH agencies and their hospital and other local partners to focus on their response to the COVID-19 pandemic.
The Centers for Medicare & Medicaid Services (CMS) Nov. 2 issued a final rule that updates physician fee schedule (PFS) payments for calendar year (CY) 2022.
The Department of Health and Human Services proposed to withdraw a rule finalized in January that requires the agency to periodically assess each regulation to determine whether it has a significant economic impact on a substantial number of small entities, and if so review the regulation to…
The AHA urged the Centers for Medicare & Medicaid Services to conduct the necessary oversight and enforcement of the No Surprises Act to ensure patients benefit from these new protections and to prevent widespread, negative consequences of any misapplication of the policy.
The AHA, joined by the Federation of American Hospitals, Michigan Health…
Health care providers registered with the Drug Enforcement Administration must use the new single-sheet form to order schedule I and II controlled substances, effective Oct. 30, the agency announced.
The U.S. Chamber of Commerce and 21 other organizations, including the AHA, urged Congress to maintain the current legal and regulatory framework for evaluating mergers and acquisitions.